Almirall Signs an Option to License Agreement with Dermira to Develop and Commercialize Lebrikizumab in EU for Atopic Dermatitis 

 Almirall Signs an Option to License Agreement with Dermira to Develop and Commercialize Lebrikizumab in EU for Atopic Dermatitis 

Almirall Signs an Option to License Agreement with Dermira to Develop and Commercialize Lebrikizumab in EU for Atopic Dermatitis 

Shots:

  • Dermira to receive $30M upfront. Almira to get exclusive option to license rights for Dermira’s lebrikizumab to develop in dermatology & commercialize it in all indications in EU, with 45 days to exercise the option on basis of its P-IIb results
  • If Almirall exercises its option, Dermira will receive $50M as option exercise fee, $30M milestones on the onset of P-III trial, $85M as regulatory milestone and on first sale in EU, and threshold milestones & royalties on net sales of lebrikizumab in EU
  • Lebrikizumab is a mAb, bind to IL-13, involved in prevention of the formation of IL-13Rα1/IL-4Rα heterodimer complex and is evaluated in P-IIb study in 280 patients with moderate-to-severe atopic dermatitis aged >18yrs.

Click here to read full press release/ article | Ref: Globe Newswire | Image: Pharmaphorum

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post